POST COVID-19, IS PHARMA AND MEDTECH COMMERCIAL MODEL OBSOLETE ?

This article, published on July 1, 2020 on LinkedIn, is jointly authored by Laurent Decory (BlueJet Consulting), Sameer Agarwal (CSA Healthcare GmbH), Cruz Lopéz (AboutDots) and Anders Krüger (Krüger CFO Services Consulting).

In this article the authors evaluate and discuss various possible changes in the commercial model in Pharma and Medtech and reflect on the various options, including remote interaction with HCPs through digital platforms and challenges thereof.